Loading...
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
BACKGROUND: We determined whether the market exclusivity incentive of the European Orphan Drug Regulation results in a market monopoly or that absence of another Orphan Medicinal Product (OMP) for the same rare disorder, a so-called follow-on OMP, is a matter of time or market size. In the interest...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3185263/ https://ncbi.nlm.nih.gov/pubmed/21892964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1750-1172-6-59 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|